07:45 AM EST, 03/07/2024 (MT Newswires) -- Neumora Therapeutics ( NMRA ) reported a Q4 loss Thursday of $0.71 per diluted share, narrower than a loss of $0.99 a year earlier.

Five analysts polled by Capital IQ expected a loss of $0.58.

As expected, the company did not report revenue for the quarter ended Dec. 31.

The company said it had $463.8 million in cash, cash equivalents and marketable securities at the end of the quarter, which it said would enable it to fund its operating plan into 2026.